Background. The Parkinson’s Disease Composite Scale (PDCS) is a recently developed easy-to-use tool enabling a timely but comprehensive assessment of Parkinson’s disease (PD)-related symptoms. Although the PDCS has been extensively validated, its responsiveness to acute levodopa challenge has not been demonstrated yet. Objective. To investigate the correlation between changes in the motor examination part of the Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and the PDCS motor scores during acute levodopa challenge and calculate a cutoff range on the PDCS indicating clinically relevant improvement. Methods. A consecutive series of 100 patients with parkinsonism were assessed using the motor examination sections of the MDS-UPDRS and the PDCS at least 12 hours after the last levodopa dose and after the administration of a single dose of a suprathreshold immediate formulation of levodopa/benserazide reaching the “best ON.” Results. There was a high correlation between changes in the MDS-UPDRS and the PDCS motor scores (Spearman’s rho = 0.73, ). Receiver operating characteristic analysis revealed that a 14.6%–18.5% improvement in the PDCS motor scores corresponds to a 20–30% improvement in the MDS-UPDRS motor examination. Conclusions. The PDCS can reliably and adequately respond to an acute levodopa challenge. Any improvements in PDCS motor scores exceeding the 14.6–18.5% threshold could represent a clinically relevant response to levodopa.

中文翻译：

---

帕金森病综合量表足以应对急性左旋多巴挑战。

背景。帕金森病综合量表 (PDCS) 是一种最近开发的易于使用的工具，能够对帕金森病 (PD) 相关症状进行及时而全面的评估。尽管 PDCS 已得到广泛验证，但其对急性左旋多巴攻击的反应尚未得到证实。客观。研究运动障碍协会赞助的统一帕金森病评定量表 (MDS-UPDRS) 运动检查部分的变化与急性左旋多巴激发期间 PDCS 运动评分之间的相关性，并计算 PDCS 上表明临床相关改善的截止范围。方法. 在最后一次左旋多巴给药后至少 12 小时，以及在单剂量左旋多巴/苄丝肼超阈值速效制剂给药后至少 12 小时，使用 MDS-UPDRS 和 PDCS 的运动检查部分对连续系列的 100 名帕金森病患者进行了评估。 “最好的”。结果S。MDS-UPDRS 的变化与 PDCS 运动评分之间存在高度相关性（Spearman's rho = 0.73, ）。接受者操作特征分析显示，PDCS 运动评分提高 14.6%–18.5% 对应于 MDS-UPDRS 运动检查提高 20–30%。结论. PDCS 能够可靠且充分地应对急性左旋多巴挑战。超过 14.6-18.5% 阈值的 PDCS 运动评分的任何改善都可能代表对左旋多巴的临床相关反应。